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Abstract
The presence of cervical lymph node metastases in head and neck squamous cell carcinoma (HNSCC) is the stron-
gest determinant of patient prognosis. Owing to the impact of nodal metastases on patient survival, a system for
sensitive and accurate detection is required. Clinical staging of lymph nodes is far less accurate than pathological
staging. Pathological staging also suffers limitations because it fails to detect micrometastasis in a subset of nodal
specimens. To improve the sensitivity of existing means of diagnosing metastatic disease, many advocate the use
of molecular markers specific for HNSCC cells. MicroRNA (miRNA) are short noncoding segments of RNA that
posttranscriptionally regulate gene expression. Approximately one third of all miRNA will exhibit substantial tissue
specificity. Using a quantitative reverse transcription–polymerase chain reaction–based assay, we examined the
expression of microRNA-205 (mir-205) across tissues and demonstrated that its expression is highly specific for
squamous epithelium. We applied this assay to tissue samples, and we could detect metastatic HNSCC in each
positive lymph node specimen, whereas benign specimens did not express this marker. When compared to metas-
tases from other primary tumors, HNSCC-positive lymph nodes were distinguishable by the high expression of this
marker. Using an in vitro lymphoid tissue model, we were able to detect as little as one squamous cell in a back-
ground of 1 million lymphocytes. By combining the sensitivity of quantitative reverse transcription–polymerase chain
reaction with the specificity of mir-205 for squamous epithelium, we demonstrate a novel molecular marker for the
detection of metastatic HNSCC.
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Introduction
For squamous cell carcinoma of the head and neck, metastasis to
regional lymph nodes is the strongest predictor of disease outcome
and prognosis [1,2]. Accurate staging of regional lymph node metas-
tases is necessary to improve both locoregional control and patient
outcomes. Unfortunately, current routine clinical and pathological
methods of detecting lymph node metastasis are suboptimal for
identifying the presence of micrometastases and may lead to the un-
derstaging of many patients with head and neck squamous cell car-
cinoma (HNSCC) [3,4]. The poor sensitivity of current clinical and
pathological methods for detecting occult micrometastases has led to
the clinical strategy of elective neck dissection (END) for patients
with a high likelihood of harboring subclinical nodal disease. Yet
END is not without morbidity and, in many cases, will constitute
overtreatment because only 50% of these patients will be found to
harbor metastatic nodal disease [5]. Even for patients whose primary
tumor size or site warrants END, routine pathological analysis of
dissected nodal specimens will fail to detect microscopic nodal me-
tastases in 8% to 20% of patients [6,7]. Routine pathologic analysis
with hematoxylin-eosin (H&E) staining is also prone to sampling
errors that can make the detection of micrometastasis difficult [8].
The limitations of routine pathology for detecting micrometastatic
disease have made it necessary to explore molecular means of diag-
nosis that can detect disease through whole or partial node sampling.
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Molecular detection of HNSCC cells in a background of lymph
node tissue demands a highly specific and sensitive biomarker. Ide-
ally, this biomarker would be abundantly yet exclusively expressed in
squamous epithelium, whereas having negligible expression in lym-
phocytes and lymphatic or vascular stroma. One method for the
molecular detection of these biomarkers that has shown promise in
recent studies is quantitative reverse transcription–polymerase chain
reaction (qRT-PCR) [9–12]. Quantitative reverse transcription–
polymerase chain reaction provides the ability to perform rapid quan-
titative analysis for biomarkers with great sensitivity and from minute
amounts of starting material. Because this technology is both rapid and
sensitive, it offers the potential to improve clinical decision making,
which is often delayed by routine histological means of diagnosis.
Recent studies have focused on the use of qRT-PCR to screen
lymph node specimens for gene (mRNA) markers that can distin-
guish benign lymph nodes from those that harbor metastatic disease
[13–15]. One set of mRNA biomarkers that is being used to detect
metastatic HNSCC is the cytokeratin proteins [10,16]. These mole-
cules, which are typically expressed in pairs, are specific for cells of
epithelial origin and are thought to be conserved during neoplastic
cell transformation [17]. Although the detection of cytokeratins
and other mRNA markers in metastatic HNSCC nodal samples
has proven feasible by both immunohistochemistry and qRT-PCR,
there is little data to suggest that mRNA biomarkers retain a high
diagnostic accuracy when applied to poorly differentiated tissue sam-
ples. Selection of an appropriate gene marker has been hampered by
the fact that gene expression in tumors can vary depending on their
degree of differentiation, and it often takes multiple gene markers to
obtain high diagnostic accuracy [18–22]. Debate currently exists
about which gene markers (either alone or in combination) will con-
vey this level of accuracy.
As upstream regulators of mRNA expression, microRNA (miRNA)
possess many characteristics that make them appealing diagnostic
biomarkers. These small (18-22nt) molecules belong to a class of
noncoding, regulatory RNA that modulate the expression of their
of gene targets. Each miRNA is estimated to control the expression
of hundreds of mRNA species [23]. These molecules also display
extraordinary tissue-specificity, and their tissue-specific nature has
already been exploited for the purpose of diagnosing and classify-
ing primary cancers and their metastases [24–28]. Evidence suggests
that miRNA biomarkes may perform more robustly than mRNA
as tumors de-differentiate. In a recent head-to-head comparison,
mRNA- and miRNA-based tissue classifiers were compared for their
ability to establish the correct diagnosis for poorly differentiated tu-
mors of uncertain origin. In their study, Lu et al. [26] discovered that
the miRNA-based classifier established a correct diagnosis with far
greater accuracy than the mRNA-based classifier, which proved
highly inaccurate for this purpose. In addition to the greater accuracy
of miRNA for poorly differentiated tissue, miRNA also maintain
their expression profile in fresh-frozen and formalin-fixed, paraffin-
embedded (FFPE) samples, permitting study of their expression in
archived pathologic samples [29,30]. This is in distinction to mRNA,
which have limited use for gene expression analysis in archived FFPE
tissues owing to mRNA degradation and modification during fixa-
tion and processing [31]. One further benefit is that miRNA remain
largely intact and are less likely than mRNA to degrade in routinely
processed tissue specimens [32]. Given these important advantages,
many are now looking to explore the potential of miRNA as tissue-
specific biomarkers of cancer and other disease states.
In the current study, we focus on the tissue-specific expression of
mir-205, which demonstrates high endogenous expression in squa-
mous epithelium. This microRNA has been reported in previous
studies to have variable expression in many human carcinoma cells
and, specifically, to be highly overexpressed in HNSCC cell lines
[33–37]. In this study, we will examine its range of expression across
many human tissues and compare its relative expression in normal
and cancerous mucosal tissues of the head and neck. We will also
explore the potential use of mir-205 as a biomarker for HNSCC
and determine its capacity to aid in the detection of overt and occult
metastatic nodal disease.
Materials and Methods
Mouse Tissue
Six-month-old male mice (C57BL/6 strain) were killed by CO2
asphyxiation. The organs were dissected, and 25 mg of each tissue
was placed immediately in Qiazol reagent (Qiagen, Valencia, CA).
Tissue was lysed with a motorized rotor-stator homogenizer in Qiazol
followed by RNA isolation using the miRNEASY minikit (Qiagen).
Mouse tissue experiments and expression analyses for each organ
were carried out in triplicate. RNA was quantified by spectropho-
tometry using a Nanodrop 1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE). Each RNA prep was characterized
for purity by an OD ratio of 260:280.
Cell Lines
The cell lines used in these experiments were derived from various
anatomic sites in patients with primary squamous cell carcinoma.
The UM-SCC-1, UM-SCC-6, UM-SCC-87, TU167, UT-SCC-
50, UM-SCC-15, and UM-SCC-5 lines were derived from primary
squamous carcinoma of the oral cavity, oropharynx, floor-of-mouth,
hypopharynx, and larynx. The Jurkat human T-cell leukemia line was
obtained from the American Type Culture Corporation (Manassas,
VA) and propagated according to established protocol. The primary
normal human oral keratinocyte (NHOK) cell line was prepared from
keratinized oral epithelial tissues according to methods described else-
where [38].
Patient Tissue Samples
Snap-frozen tissue from 12 surgically removed, pathologically con-
firmed, primary HNSCC samples from various subsites in the head
and neck and 7 benign mucosal tissue samples derived from the oral
cavity or oropharynx were collected from the University of Iowa
Department of Pathology after approval by the institutional review
board. Patient demographics and tumor characteristics for each pri-
mary sample are listed in Table W1. A total of eight histologically
determined HNSCC-positive lymph nodes were included in this
study. The patient demographics and primary tumor characteristics
for each HNSCC-positive specimen are listed in Table W2. For
negative controls, lymph nodes were obtained from cancer-free pa-
tients who had undergone lymph node removal for the diagnosis
or treatment of benign disorders, nd whose specimen was determined
by the pathologist to be either “benign” or “benign reactive.” In total,
benign nodal samples were obtained from five separate patients.
For comparison, we included three lymph node samples each con-
taining metastatic adenocarcinoma of the lung and breast as well as
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metastatic melanoma. All tumors and metastatic lymph node speci-
mens were classified according to the widely accepted diagnostic his-
tological criteria.
RNA Isolation and cDNA Synthesis
RNA was isolated using the miRNeasy minikit (Qiagen) accord-
ing to the protocol described by the manufacturer. cDNA was gen-
erated from the total RNA sample by reverse transcription using the
TaqMan Mir-205 assay kit (Applied Biosystems, Foster City, CA).
This kit uses gene-specific stem-loop reverse transcription primers
and TaqMan probes to detect mature miRNA transcripts in a two-step
qRT-PCR assay. Briefly, each RT reaction contained 10 ng of total
RNA, 50 nM stem-looped RT primer, 1× RT buffer, 0.25 mM each
of dNTPs, 3.33 U/μl Multiscribe reverse transcriptase, and 0.25 U/μl
RNase inhibitor. The 20-μl reactions were incubated in a Thermo-
cycler in a 96-well plate for 30 minutes at 16°C, 30 minutes at 42°C,
5 minutes at 85°C, and then held at 4°C.
Real-time qRT-PCR
Real-time PCR was performed using a standard TaqMan PCR kit
protocol on an Applied Biosystems 7500 fast Sequence Detection
System. The 20-μl PCR included 1.33 μl of RT product, 10 μl of
1× TaqMan Universal PCR Master Mix (P/N: 4324018; Applied
Biosystems), 1.0 μl of the 20× TaqMan MicroRNA assay (contains
primer and probe), and 7.67 μl of nuclease-free water. Each 20-μl
volume was run in triplicate. The reactions were incubated in a
96-well plate at 95°C for 10 minutes, followed by 40 cycles of 95°C
for 15 seconds, and 60°C for 1 minute.
Expression Analysis
Quantitation of mature miRNA expression levels in cell and tissue
samples was performed on the ABI 7500 Real-Time PCR System.
Each sample was run in triplicate. Endogenous controls were used
for the normalization of RNA input: small nucleolar RNA RNU48
and snoRNA202 for human and mouse tissues, respectively. To eval-
uate the appropriateness of these endogenous controls for use in these
tissues, their expression levels were determined in multiple tissue
samples. All samples demonstrated low variability in their expression,
thus validating their use as normalization controls. MiRNA expres-
sion levels were calculated by relative quantitation using the ABI
7500 Real-Time PCR SDS software version 1.4 (Applied Biosys-
tems), and the fold expression changes were determined by 2−ΔΔCT
method [39]. The data are presented as the fold-expression change
of mir-205 expression in tumors and metastatic lesions relative to
their corresponding normal tissues after normalization to the endog-
enous control.
Results
Tissue-Specific Expression of mir-205
To characterize the range of expression of mir-205 across mamma-
lian tissues, we extracted total RNA from various mouse tissues and
performed qRT-PCR analysis for mir-205. Ten nanograms of total
RNA from each sample was subjected to qRT-PCR, and the expres-
sion of mir-205 was determined after normalization to the endoge-
nous control (snoRNA202). A calibrator sample was selected from
among the tissues whose expression of mir-205 was determined
through repeat experiments to be negligible. On the basis of the
low endogenous expression of mir-205, spleen was selected as the
1× sample for the purpose of calibration, and the expression of
mir-205 in the other tissues was measured relative to it. MiRNA
expression levels were calculated by relative quantitation using the
2−ΔΔCT method. The data are presented as the n-fold expression
difference of each tissue relative to the calibrator sample. The ex-
pression of mir-205 is highest in tissues composed of or lined with
squamous epithelium and is lower in parenchymal organs such as
kidney, liver, and brain (Figure 1). Our experimental findings are
in keeping with previously published studies, which suggest that
mir-205 exhibits high endogenous expression in a broad range of
tissues containing squamous epithelia [36]. Whereas the function
of mir-205 in these tissues remains to be elucidated, its predictable
pattern of expression validates its potential use as a tissue-specific di-
agnostic marker.
Expression of mir-205 in HNSCC Cell Lines and
Tissue Samples
Real-time expression analysis of mir-205 in HNSCC cell lines
showed that mir-205 is abundantly expressed, with no significant dif-
ference in expression when normalized to the NHOK cell line. Our
relative expression analysis as determined by the 2−ΔΔCTmethod dem-
onstrates a less than twofold variance in the expression of mir-205
in all HNSCC when compared to NHOKs (Figure 2A). Using a
threefold expression difference as the minimum cutoff, there is no
significant change in the expression of mir-205 as squamous epithe-
lial cells transition from benign to neoplastic. These results are in
contradistinction to the assertion by Tran et al. [33] that mir-205
was “exclusively overexpressed” in HNSCC. These results also under-
score the importance of proper tissue normalization for relative ex-
pression studies.
Results of real-time qRT-PCR amplification of mir-205 in HNSCC
tissue samples were concordant with that obtained from the HNSCC
cell lines. Total RNA from each tumor specimen was subjected to
Figure 1. Tissue-specific expression of mir-205. The relative fold
expression difference of mir-205 in each sample relative to the cal-
ibrator sample (spleen).
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qRT-PCR for mir-205, and the mir-205 expressions in tumors from
the same anatomic subsite were averaged together during the relative
expression analysis. Expression of mir-205 showed minimal variance
among tumors from different head and neck subsites. There was also
little variance among biological replicates. The reduction in relative
expression of mir-205 was less than twofold for each tumor when
compared to the average expression of the benign mucosal samples
(Figure 2B). These findings are consistent with previously published
data suggesting that there is a slight reduction in the expression of
tissue-specific miRNA between cell lines and their corresponding pri-
mary tissue [37]. Because the expression of mir-205 does not change
significantly during the neoplastic transformation of squamous cells,
its expression will not be useful for the purpose of distinguishing
HNSCC cells from normal squamous epithelium. However, its pre-
dictable pattern of expression offers unique diagnostic capability in-
sofar as it is not expressed appreciably in lymph node tissue and can
thus prove useful for the detection of lymph node metastases.
Detection of Metastatic HNSCC in Lymph Node
Tissue Samples
To demonstrate the potential of mir-205 to detect metastatic
HNSCC in lymph node tissue samples by qRT-PCR, we analyzed
a set of five benign and eight histologically positive nodes for expres-
sion of mir-205. Each lymph node designated as “benign” had un-
dergone routine pathological analysis with H&E staining and was
determined to have no gross or microscopic evidence of tumor. Total
RNA was extracted from each lymph node sample, and the relative
expression of mir-205 was measured by qRT-PCR. Using this assay,
we were able to distinguish positive from benign nodes on the basis
of mir-205 expression. The aggregate mir-205 expression in the eight
histologically positive nodes was calibrated against the aggregate ex-
pression in the benign nodal samples and then normalized to the en-
dogenous control (RNU48). In each of the eight positive nodes, we
were able to detect a significant increase in the relative expression of
mir-205 compared to benign samples that had a negligible expression
of mir-205 (Figure 3). The data are presented as the average relative
Figure 2. Expression of mir-205 in cell lines and tissue samples.
(A) The expression of mir-205 in the HNSCC cell lines after normal-
ization to the NHOK cell line. (B) The expression of mir-205 in pri-
mary tissue from various anatomical subsites after normalization
to normal mucosal tissue.
Figure 3. Expression of mir-205 in metastatic lymph node samples. The fold expression difference in mir-205 for each specimen relative
to the benign node samples (error bars indicate SD for each sample).
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fold expression change in the aggregate of each sample type (benign
and positive).
For comparison, we included three samples each of lymph node
tissue containing pathologically confirmed adenocarcinoma of the
lung and breast and three samples containing metastatic melanoma.
Each lymph node sample was processed as described above, and the
expression of mir-205 was measured by qRT-PCR. The aggregate
mir-205 expression in each sample type was calibrated against the
aggregate expression in the benign nodal samples and normalized
to the endogenous control. As seen in Figure 3, the expression of
mir-205 in the HNSCC-positive lymph node samples was several
hundred-fold higher than the other metastatic lesions when normal-
ized to the benign lymph node samples. Of significance, the relative
expression difference of mir-205 in the metastatic breast adenocarci-
noma sample was above the threefold cutoff value of significance, as
this sample averaged an eightfold higher expression of mir-205. On
the basis of previously published results, breast adenocarcinoma is
expected to express a relatively low level of mir-205 [25,40,41]. Al-
though this relative expression difference was greater than the mini-
mum level of significance, its expression was still much lower than
the expression demonstrated by the HNSCC-positive samples. This
allows for distinction between the two sample types based on mir-
205 expression, as the relative expression in an HNSCC-positive
lymph node should be several hundred-fold higher than a breast
adenocarcinoma–positive lymph node. The difference in the relative
expression of mir-205 between benign and metastatic lymph node
samples demonstrates the potential of this marker to detect meta-
static squamous cell carcinoma in lymph node specimens as well
its ability of to distinguish among metastases from different primary
tumor types.
Sensitivity Analysis of mir-205 to Detect HNSCC Cells in a
Lymphoid Background
To demonstrate the sensitivity of qRT-PCR for detecting meta-
static and micrometastatic HNSCC within lymph nodes, the squa-
mous cell cancer cell line UM-SCC1 was diluted with Jurkat cells, an
immortalized, human T-cell leukemia line at ratios ranging from
1:100 to 1:1 million (SCC-1 to Jurkat) cells. This was done to de-
termine the ability of this molecular technique to detect isolated
HNSCC metastases at concentrations less than detectable by stan-
dard histological techniques. Total RNA was then isolated from each
cellular mixture, and 10 ng of total RNA from each mixture was
subjected to qRT-PCR for mir-205. No mir-205 was detected by
qRT-PCR in the Jurkat cell line when examined alone. MicroRNA-
205 could be detected in each cellular mixture, and the fold expression
difference for each mixture relative to the Jurkat-only cell normaliza-
tion standard was more than the minimum threefold cutoff (Figure 4).
As little as one SCC-1 cell could be detected from a background of 1 ×
106 mononuclear cells by means of its mir-205 expression. These ex-
periments demonstrate the sensitivity of qRT-PCR for detecting this
marker from only a few metastatic cells, highlighting the use of this
technique for whole or partial node sampling in the detection of mi-
crometastatic disease.
Discussion
Reported here are the results of the first detailed study to examine
the use of a highly tissue-specific miRNA to detect metastatic tumor
from lymph node samples. Expression profiling of multiple organs
and tissues demonstrated that mir-205 is abundantly expressed in
squamous epithelial cells and that this expression remains relatively
constant as these tissues transition from normal to neoplastic. Signif-
icantly, mir-205 is not expressed in normal lymph node tissue, allow-
ing for the use of whole-lymph node processing and quantitative
analysis by PCR to detect this biomarker. The sensitivity of patho-
logical analysis by H&E staining for the detection of small tumor
deposits in lymph nodes has been improved by the addition of
immunohistochemical staining, which has been demonstrated to
up-stage many patients who were classified as having no clinically
measurable metastatic disease [17]. However, this technique suffers
from the limitations of cost and time consumption that make it un-
suitable for rapid diagnostic and clinical decision making.
These drawbacks directed the search for a more sensitive means of
discovering metastasis with molecular markers that are detectable by
more rapid techniques such as qRT-PCR. Early studies focused on
the detection of clonal genetic changes that were specific for HNSCC
tumor cells, such as mutations in p53 [42]. In recent years, research-
ers have shifted focus from tumor-specific markers toward tissue-
specific markers, as they seek to take advantage of the differential
gene expression of HNSCC cells and other tissues such as lymph
nodes or serum [11,12,43].
Because microRNA play a crucial role in the development, differ-
entiation, and functioning of organs and because they display re-
markable tissue-specificity [44–46], these small molecules are ideal
for use as tissue classifiers. We have demonstrated the high endog-
enous expression of mir-205 in normal and cancerous squamous
epithelial cells and its low expression in lymph node tissue. These
tissue-specific differences in mir-205 expression make it a worthy
biomarker for detecting small numbers of cells (which cannot be de-
tected by traditional means) through PCR amplification. Although
our findings suggest that mir-205 is not useful as a marker of ma-
lignant transformation of squamous epithelial cells, its consistent
expression makes it a reliable surrogate marker for the presence of
squamous epithelium. As we have demonstrated, an additional benefit
of this squamous epithelial-specific marker is its capacity to distinguish
among metastatic lesions from different tumor types. Although further
study is needed, which includes more tumor types, our findings hold
potential for assisting in the determination of primary tumor site for
metastases of unknown origin.
To date, few studies have sought to use the tissue-specific nature of
microRNA for the purpose of molecular diagnostics. This is primarily
Figure 4. Sensitivity of qRT-PCR todetectmir-205. The relativeexpres-
sion of each cell dilution when compared to the Jurkat-only sample.
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because our knowledge of tissue-specific microRNA is still emerging.
Despite this, the demand for sensitive yet specific biomarkers that
can be selectively amplified by PCR will likely make microRNA
the next step in the evolution of molecular diagnostics. MiRNA bio-
markers convey specific advantages over their mRNA counterparts.
MiRNA have a more robust profiling performance than mRNA in
de-differentiated tumor samples [23,26,27] and because they show
improved stability in routinely processed clinical samples, they may
be more suitable for study in some tissue samples. Owing to their
superior stability, miRNA are also extracted more easily from ar-
chived FFPE samples and do not undergo as much degradation dur-
ing fixation and processing [29,30]. This allows for miRNA profiling
in some tissue samples that are unfit for mRNA expression analysis.
The use of miRNA as biomarkers for the diagnosis of HNSCC is
showing early promise. In a recent study, Wong et al. [47] found that
elevated plasma levels of mir-184 were associated with the presence
of primary squamous cell carcinoma of the tongue. Along with the
screening potential demonstrated by miRNA, they have also proven
useful for the prediction of patient prognosis in some solid tumors
[48,49]. Indeed, as we begin to understand more about the expres-
sion of miRNA in benign and cancerous mucosal tissues (as well as
their associated functions), we will add another potent diagnostic
tool to our armamentarium. It remains to be determined whether
the addition of other tissue-specific miRNA markers will improve
the sensitivity of this technique for identifying occult HNSCC me-
tastases. We believe, however, that our study will give credence to the
use of mir-205 as a squamous epithelial-specific marker capable of
detecting occult metastatic tumor deposits. These data lay a founda-
tion for additional studies that examine the use of microRNA to help
solve the existing diagnostic and staging dilemmas that exist in the
treatment of HNSCC.
A comparison study is needed to determine the efficacy of mir-205
relative to existing mRNA markers for the detection of HNSCC me-
tastases. In addition, future study should focus on determining a
minimum threshold of detection for this marker, as this would help
reduce the risk of false-positive results. Our demonstration of this
highly discriminatory assay for the detection of small tumor deposits
will hopefully supply the pilot data needed to incorporate this tech-
nique into a clinically relevant application that will improve our abil-
ity to properly stage patients with metastatic HNSCC.
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Table W1. Clinical and Demographic Data of Tumor Specimens Obtained from Patients with
HNSCC in This Study.
Patient No. Age (years) Gender Specimen Stage Degree of
Differentiation
1 50 Male Primary subglottis T2 N0 Poor
2 62 Male Primary supraglottis T4 N2 Moderate
3 64 Female Primary floor of mouth T2 N0 Well
4 52 Male Primary hypopharynx T2 N1 Poor
5 86 Female Primary subglottis T2 N0 Well
6 73 Male Primary tongue T2 N0 Well
7 42 Male Primary tongue T1 N0 Well
8 56 Male Primary floor of mouth T2 N0 Moderate
9 66 Male Primary supraglottis T3 N2b Moderate
10 55 Female Primary larynx T3 N2b Moderate
11 46 Male Primary tonsil T3 N2 Moderate
12 47 Female Primary larynx T2 N2c Poor
Table W2. Clinical and Demographic Data of Metastatic Lymph Node Specimens from Patients
Included in This Study.
Patient No. Age (years) Sex Specimen Stage
1 56 Male Nodal metastasis T3 N1
2 66 Female Nodal metastasis T3 N2b
3 62 Male Nodal metastasis T4 N2
4 59 Male Nodal metastasis T2 N1
5 48 Female Nodal metastasis T3 N1
6 57 Male Nodal metastasis T2 N2
7 61 Male Nodal metastasis T3 N2
8 52 Female Nodal metastasis T2 N1
